Listing timing unconfirmed
Last verified 23 Oct 2026The previously expected date of 23 Oct 2026 has passed. Trading has not been confirmed.
- Indicative valuation
- $833.5M to $937.7MBasic equity value after the offering
- Price range
- $16.00 to $18.00Per share · USD
- Offering size
- $235.2M to $264.6MBase offering, before overallotment
- Previously expected
- 23 Oct 2026Listing timing unconfirmed
Company overview
Lycia Therapeutics websiteLycia Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapeutics that target extracellular proteins. Its initial focus is autoimmune, inflammatory and allergic diseases.
- Company country
- United States
Offering details
USD · Base offering, before overallotment
- Exchange
- Nasdaq Global Market
- Ticker
- LYCA
- Shares offered
- 14,700,000
- Shares after offering
- 52,094,559
- New shares
- 14,700,000
- Existing shares sold
- 0
- Gross proceeds to company
- $235.2M to $264.6M
- Gross proceeds to shareholders
- $0 to $0
IPO timeline
- Registration filed
- Proposed terms published
- Proposed terms published
- Proposed terms published
- Proposed terms published
- Previously expected first trading day · Estimated date
Filings and documents
- View document
- Updated offering termsChecked 21 Oct 2026 (undated source)View document
- Updated offering termsChecked 20 Oct 2026 (undated source)View document
- View document
- View document
- View document
- View document